Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes - PubMed (original) (raw)
Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes
Andrew A Acheampong et al. Drug Metab Dispos. 2002 Apr.
Abstract
The objectives of the study were to evaluate the distribution of brimonidine (alpha2-adrenergic agonist) into anterior and posterior ocular tissues. Single or multiple doses of a 0.2 or 0.5% brimonidine tartrate solution were administered to one or both eyes of monkeys or to one eye of rabbits. Brimonidine was administered intraperitoneally to rats. After topical administration, [14C]brimonidine was rapidly absorbed into the cornea and conjunctiva and distributed throughout the eye. [14C]Radioactivity was higher and cleared more slowly in pigmented tissues (iris/ciliary body, choroid/retina, and optic nerve) than in nonpigmented tissues. Single and multiple dosing led to a similar drug distribution, with higher levels of brimonidine measured in pigmented tissues after multiple dosing. Most of the radioactivity extracted from ocular tissues represented unchanged brimonidine. In the rabbits and the monkey treated in only one eye, levels of radioactivity in the untreated eye were low, consistent with the low systemic levels and rapid drug clearance. Posterior ocular tissue concentrations of radioactivity exceeded systemic blood concentrations. The vitreous humor brimonidine concentrations in monkeys treated topically with 0.2% brimonidine tartrate was 82 +/- 45 nM. Vitreous levels in rabbits confirmed the penetration of brimonidine to the posterior segment. Similar concentrations of brimonidine (22 to 390 nM) were measured in the vitreous and retina of rats injected intraperitoneally with brimonidine. Both topically applied and systemically administered brimonidine reach the back of the eye at nanomolar concentrations sufficient to activate alpha2-adrenergic receptors. The brimonidine levels achieved at the retina are relevant for neuroprotection models.
Similar articles
- The Relationship of Brimonidine Concentration in Vitreous Body to the Free Concentration in Retina/Choroid Following Topical Administration in Pigmented Rabbits.
Shinno K, Kurokawa K, Kozai S, Kawamura A, Inada K, Tokushige H. Shinno K, et al. Curr Eye Res. 2017 May;42(5):748-753. doi: 10.1080/02713683.2016.1238941. Epub 2016 Nov 17. Curr Eye Res. 2017. PMID: 27854122 - Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits.
Acheampong AA, Shackleton M, Tang-Liu DD. Acheampong AA, et al. Drug Metab Dispos. 1995 Jul;23(7):708-12. Drug Metab Dispos. 1995. PMID: 7587958 - Ocular Pharmacokinetics of Brimonidine Drug Delivery System in Monkeys and Translational Modeling for Selection of Dose and Frequency in Clinical Trials.
Tamhane M, Luu KT, Attar M. Tamhane M, et al. J Pharmacol Exp Ther. 2021 Sep;378(3):207-214. doi: 10.1124/jpet.120.000483. Epub 2021 Jul 1. J Pharmacol Exp Ther. 2021. PMID: 34210753 - Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review.
Saylor M, McLoon LK, Harrison AR, Lee MS. Saylor M, et al. Arch Ophthalmol. 2009 Apr;127(4):402-6. doi: 10.1001/archophthalmol.2009.9. Arch Ophthalmol. 2009. PMID: 19365015 Review. - Drug-induced toxic reactions in the eye: an overview.
Abdollahi M, Shafiee A, Bathaiee FS, Sharifzadeh M, Nikfar S. Abdollahi M, et al. J Infus Nurs. 2004 Nov-Dec;27(6):386-98. doi: 10.1097/00129804-200411000-00004. J Infus Nurs. 2004. PMID: 15586102 Review.
Cited by
- Comprehensive Pharmacokinetic Evaluation of High Melanin Binder Levofloxacin in Rabbits Shows Potential of Topical Eye Drops for Posterior Segment Treatment.
Bahrpeyma S, Jakubiak P, Alvarez-Sánchez R, Caruso A, Leuthardt M, Senn C, Del Amo EM, Urtti A. Bahrpeyma S, et al. Invest Ophthalmol Vis Sci. 2024 Oct 1;65(12):14. doi: 10.1167/iovs.65.12.14. Invest Ophthalmol Vis Sci. 2024. PMID: 39382881 Free PMC article. - Exploring Neuroprotective Effects of Topical Brimonidine in Experimental Diabetic Retinopathy.
Jung KI, Kim JH, Han JS, Park CK. Jung KI, et al. In Vivo. 2024 Jul-Aug;38(4):1609-1620. doi: 10.21873/invivo.13611. In Vivo. 2024. PMID: 38936912 Free PMC article. - Patient Factors Influencing Intraocular Penetration of Brimonidine-Related Eye Drops in Adults: A Post Hoc Pooled Analysis.
Kunikane E, Orii Y, Inoue A, Inatani M. Kunikane E, et al. Ophthalmol Ther. 2023 Dec;12(6):3083-3098. doi: 10.1007/s40123-023-00794-x. Epub 2023 Sep 7. Ophthalmol Ther. 2023. PMID: 37676633 Free PMC article. - Three Major Causes of Metabolic Retinal Degenerations and Three Ways to Avoid Them.
Kovács-Valasek A, Rák T, Pöstyéni E, Csutak A, Gábriel R. Kovács-Valasek A, et al. Int J Mol Sci. 2023 May 13;24(10):8728. doi: 10.3390/ijms24108728. Int J Mol Sci. 2023. PMID: 37240082 Free PMC article. Review. - Topical Treatment for Retinal Degenerative Pathologies: A Systematic Review.
Samoilă L, Voștinaru O, Dinte E, Bodoki AE, Iacob BC, Bodoki E, Samoilă O. Samoilă L, et al. Int J Mol Sci. 2023 Apr 28;24(9):8045. doi: 10.3390/ijms24098045. Int J Mol Sci. 2023. PMID: 37175752 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical